StockNews.com Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell

StockNews.com downgraded shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a hold rating to a sell rating in a research note published on Friday morning.

Separately, LADENBURG THALM/SH SH boosted their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a buy rating in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Corvus Pharmaceuticals currently has an average rating of Hold and a consensus price target of $10.83.

Corvus Pharmaceuticals Stock Performance

CRVS stock opened at $5.28 on Friday. The firm has a fifty day moving average price of $4.03 and a 200 day moving average price of $2.63. Corvus Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $6.15. The firm has a market cap of $330.27 million, a PE ratio of -10.15 and a beta of 1.13.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.05. During the same quarter in the prior year, the company earned ($0.14) earnings per share. On average, equities analysts predict that Corvus Pharmaceuticals will post -0.45 EPS for the current year.

Institutional Trading of Corvus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC purchased a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $44,000. Marshall Wace LLP purchased a new stake in Corvus Pharmaceuticals in the second quarter valued at approximately $136,000. Towerview LLC lifted its stake in Corvus Pharmaceuticals by 4.6% during the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after acquiring an additional 17,500 shares during the period. Vanguard Group Inc. lifted its stake in Corvus Pharmaceuticals by 10.6% during the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after acquiring an additional 142,724 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $10,855,000. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.